You are here:

MS in the Media - 18 May 2018

Published on

12 - 18 May 2018

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

NICE approves injectable drugs for relapsing MS

NICE have approved all of the injectable disease modifying drugs for relapsing MS, other than Plegridy, which will be looked at separately, and Betaferon.  NICE's initial suggestion was to only allow one drug (Extavia), but the companies brought their prices down to allow them to go through.

Source: NICE
Source: Pharma Times

MS Trust link: NICE revises decision to restrict drugs for relapsing MS

Gilenya approved for young Americans

The US drug regulator, the FDA, has approved Gilenya (fingolimod) as a treatment for people aged 10 to 18 with relapsing MS - the first disease modifying drug for this age group. NICE will begin the process of assessing the drug for use with this age group by the NHS in England at the end of May  

Source: FDA
Source: National MS Society (USA)

MS Trust link: Gilenya (fingolimod)

AAN meeting round up

A round up of topics covered April's meeting of the Academy of American Neurologists (AAN).  Includes early vs later treatment, laquinimod, stem cells, Gilenya (fingolimod), childhood MS, new disease modifying drug guidelines, progression, biomarkers, cognition, telemedicine, fish, risk factors and puberty.

Source: National MS Society (USA)

MS Trust link: MS research updates

RCN supports medical cannabis

At its congress in Belfast, the Royal College of Nursing (RCN) has voted in favour of the legalisation of cannabis for medical use.

Source: Daily Telegraph

MS Trust link: Cannabis

Vitamins and dietary supplements

A review of studies of vitamin and dietary supplements found that only vitamin D had any clear benefit for people with MS. A number of other vitamins and supplements showed some effects but none of the findings reached statistical significance.

Source: Neurology Advisor

MS Trust link: Vitamin D